156969-42-5 Usage
General Description
Pyrazolo[1,5-a]pyridin-5-ol, also known as alpidem, is a chemical compound that belongs to the class of pyrazolopyridine derivatives. It is used as a medicinal drug and is primarily known for its sedative and anxiolytic properties. Alpidem acts as a positive modulator of the benzodiazepine receptor, which is a component of the GABA-A receptor complex, leading to its effects on the central nervous system. It has been studied for its potential use in treating various neurological and psychiatric disorders, including anxiety and insomnia. However, its use has been limited due to concerns about its safety and potential for abuse.
Check Digit Verification of cas no
The CAS Registry Mumber 156969-42-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,6,9,6 and 9 respectively; the second part has 2 digits, 4 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 156969-42:
(8*1)+(7*5)+(6*6)+(5*9)+(4*6)+(3*9)+(2*4)+(1*2)=185
185 % 10 = 5
So 156969-42-5 is a valid CAS Registry Number.
156969-42-5Relevant articles and documents
Efficient salt-induced kinase inhibitor and preparation method thereof
-
, (2021/09/04)
The invention discloses an efficient salt-induced kinase inhibitor and a preparation method thereof, and the efficient salt-induced kinase inhibitor is characterized by comprising substances of a chemical formula in the invention. The salt-induced kinase inhibitor with excellent performance has high inhibitory activity for in-vitro experiments and also has high cell inhibitory activity.
AMIDO-BENZYL SULFONE AND SULFOXIDE DERIVATIVES
-
, (2013/09/12)
The present invention relates to certain amido-benzyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.
AMIDO-BENZYL SULFOXIDE DERIVATIVES
-
, (2013/09/12)
The present invention relates to certain amido-benzyl sulfoxide compounds, pharmaceutical compositions comprising such compounds, and methods of treatment of an NAMPT-mediated disease or condition in a subject, selected from solid or liquid tumor, rheumat